Definitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience

Zamaniah, W.I. Wan; Mastura, M.Y.; Phua, C.E.; Adlinda, A.; Marniza, S.; Rozita, A.M.

추천

검색

자료유형: 학술저널

저자정보: Zamaniah, W.I. Wan (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) Mastura, M.Y. (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) Phua, C.E. (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) Adlinda, A. (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) Marniza, S. (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) Rozita, A.M. (Clinical Oncology Unit, Faculty of Medicine, University of Malaya)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제20호

발행연도: 2014.1

수록면: 8,987 - 8,992 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The efficacy of concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer is well established. We aimed to investigate the long-term efficacy of definitive concurrent chemoradiotherapy for cervical cancer in the University of Malaya Medical Centre. Materials and Methods: A cohort of 60 patients with FIGO stage IB2-IVA cervical cancer who were treated with definitive concurrent chemoradiotherapy with cisplatin followed by intracavitary brachytherapy or external beam radiotherapy (EBRT) boost between November 2001 and May 2008 were analysed. Patients were initially treated with weekly intravenous cisplatin ($40mg/m^2$) concurrent with daily EBRT to pelvis of 45-50Gy followed by low dose rate brachytherapy or EBRT boost to tumour. Local control rate, progression free survival, overall survival and treatment related toxicities graded by the RTOG criteria were evaluated. Results: The mean age was 56. At the median follow-up of 72 months, the estimated 5-year progression-free survival (PFS) (median PFS 39 months) and the 5-year overall survival (OS) (median OS 51 months) were 48% and 50% respectively. The 5-year local control rate was 67.3%. Grade 3-4 late gastrointestinal and genitourinary toxicity occurred in 9.3% of patients. Conclusions: The 5-year PFS and the 5-year OS in this cohort were lower than in other institutions. More advanced stage at presentation, longer overall treatment time (OTT) of more than fifty-six days and lower total dose to point A were the potential factors contributing to a lower survival.

#Cervical cancer #concurrent chemoradiotherapy #progression free survival #overall survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요